Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Bristol-Myers Squibb Co. has announced ... s existing portfolio of products, which has a main focus on the R&amp,D of treatments for patients with type 2 diabetes. AstraZeneca will pay Bristol ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

Bristol-Myers Squibb was founded in 1858 and has grown to be one of today's leading global pharmaceutical companies. For over 150 years, Bristol-Myers Squibb (BMS) has been committed to "discover ...

Looking ahead, Bristol-Myers Squibb faces the challenge of maintaining top-line growth in the face of patent expirations and increasing competition. The company's guidance for key products like ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions. Therefore many companies in this sector are somewhat insulated from the ...

Bristol Myers Squibb said it will acquire its struggling CAR-T partner 2Seventy Bio for $286 million, or $102 million net of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Bristol Myers Squibb is one of these. The drugmaker has a deep lineup of products across areas such ... a medical-device specialist that focuses on diabetes care. The company develops continuous ...